Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $38.00 | $3.80/mg | In stock | Jul 4 |
| vial | 10mg | $105.00 | $10.50/mg | In stock | Jul 4 |
| vial | 10mg | $150.00 | $15.00/mg | In stock | Jul 4 |
| vial | 10mg | $225.00 | $22.50/mg | In stock | Jul 4 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| PSCSLK10001 | — | 99.6% | Freedom Diagnostics | — | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. Selank is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Peptide Supply Co. sell Selank?
Yes — Peptide Supply Co. currently lists Selank in 4 variants starting at $38.00 ($3.80/mg).
Is Peptide Supply Co.'s Selank third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Peptide Supply Co.'s Selank, with the most recent showing 99.6% purity. Peptide Supply Co. holds an overall trust grade of B (81/100) across all 137 COAs on file.
What is Peptide Supply Co.'s trust grade for Selank?
Peptide Supply Co. has an overall Disclosed Labs trust grade of B (81/100), computed from 137 COAs across all peptides. The most recent Selank COA was issued by Freedom Diagnostics.
Where is the cheapest Selank?
As of the latest data, Verified Peptides offers Selank at $1.60/mg — compare with Peptide Supply Co.'s listing at $3.80/mg. See the full Selank price comparison.
Is Selank legal to buy?
Selank is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.